Cargando…

The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis

Previous studies have determined that aberrant expression of the fas-associated death domain (FADD) contributes to the development of cancer. However, no pan-cancer analysis has been reported to explore the relationship between FADD and various cancers. Multiple databases were screened to identify c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chenyu, Jiang, Xianglai, Zhao, Qiqi, Xie, Zhiyuan, Cai, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565789/
https://www.ncbi.nlm.nih.gov/pubmed/37829257
http://dx.doi.org/10.3892/br.2023.1659
_version_ 1785118772141490176
author Wang, Chenyu
Jiang, Xianglai
Zhao, Qiqi
Xie, Zhiyuan
Cai, Hui
author_facet Wang, Chenyu
Jiang, Xianglai
Zhao, Qiqi
Xie, Zhiyuan
Cai, Hui
author_sort Wang, Chenyu
collection PubMed
description Previous studies have determined that aberrant expression of the fas-associated death domain (FADD) contributes to the development of cancer. However, no pan-cancer analysis has been reported to explore the relationship between FADD and various cancers. Multiple databases were screened to identify cancer datasets for the present study and to validate the expression of FADD in various tumors. The association of FADD alteration with cancer prognosis, clinical features and tumor immunity was also evaluated. Reverse transcription-quantitative PCR (RT-qPCR) was utilized to confirm the expression of FADD in breast, colon, liver and gastric cancer cells. Analysis of Gene Expression Omnibus database and The Cancer Genome Atlas database indicated that FADD was highly expressed in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD) and prostate adenocarcinoma, whereas RT-qPCR results revealed that FADD was highly expressed in breast cancer and colon cancer. Further analyses demonstrated that FADD expression was significantly altered in ESCA, head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma and BRCA. FADD expression was observed to be a risk factor of the overall survival in patients with HNSC, LIHC and LUAD as demonstrated by Kaplan-Meier and Cox regression analyses. The results of the present study demonstrated that FADD is highly expressed in numerous malignancies and can be utilized as a biomarker for the diagnosis of BRCA, COAD, LIHC and stomach adenocarcinoma. Moreover, FADD expression is a predictive risk factor for the development of HNSC, LIHC and LUAD and can potentially be used as a prognostic marker for these cancers.
format Online
Article
Text
id pubmed-10565789
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-105657892023-10-12 The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis Wang, Chenyu Jiang, Xianglai Zhao, Qiqi Xie, Zhiyuan Cai, Hui Biomed Rep Articles Previous studies have determined that aberrant expression of the fas-associated death domain (FADD) contributes to the development of cancer. However, no pan-cancer analysis has been reported to explore the relationship between FADD and various cancers. Multiple databases were screened to identify cancer datasets for the present study and to validate the expression of FADD in various tumors. The association of FADD alteration with cancer prognosis, clinical features and tumor immunity was also evaluated. Reverse transcription-quantitative PCR (RT-qPCR) was utilized to confirm the expression of FADD in breast, colon, liver and gastric cancer cells. Analysis of Gene Expression Omnibus database and The Cancer Genome Atlas database indicated that FADD was highly expressed in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma, cholangiocarcinoma, colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD) and prostate adenocarcinoma, whereas RT-qPCR results revealed that FADD was highly expressed in breast cancer and colon cancer. Further analyses demonstrated that FADD expression was significantly altered in ESCA, head and neck squamous cell carcinoma (HNSC), lung squamous cell carcinoma and BRCA. FADD expression was observed to be a risk factor of the overall survival in patients with HNSC, LIHC and LUAD as demonstrated by Kaplan-Meier and Cox regression analyses. The results of the present study demonstrated that FADD is highly expressed in numerous malignancies and can be utilized as a biomarker for the diagnosis of BRCA, COAD, LIHC and stomach adenocarcinoma. Moreover, FADD expression is a predictive risk factor for the development of HNSC, LIHC and LUAD and can potentially be used as a prognostic marker for these cancers. D.A. Spandidos 2023-09-11 /pmc/articles/PMC10565789/ /pubmed/37829257 http://dx.doi.org/10.3892/br.2023.1659 Text en Copyright: © Wang et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Wang, Chenyu
Jiang, Xianglai
Zhao, Qiqi
Xie, Zhiyuan
Cai, Hui
The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis
title The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis
title_full The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis
title_fullStr The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis
title_full_unstemmed The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis
title_short The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis
title_sort diagnostic or prognostic values of fadd in cancers based on pan‑cancer analysis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10565789/
https://www.ncbi.nlm.nih.gov/pubmed/37829257
http://dx.doi.org/10.3892/br.2023.1659
work_keys_str_mv AT wangchenyu thediagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT jiangxianglai thediagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT zhaoqiqi thediagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT xiezhiyuan thediagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT caihui thediagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT wangchenyu diagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT jiangxianglai diagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT zhaoqiqi diagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT xiezhiyuan diagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis
AT caihui diagnosticorprognosticvaluesoffaddincancersbasedonpancanceranalysis